Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naporafenib and trametinib in RAS Q61X solid tumors
NCT05907304Phase 1Active, not recruiting
- Sponsor
- Erasca
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of naporafenib in solid tumor, sponsored by Erasca. Primary endpoint: Efficacy of naporafenib administered with trametinib at 24 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
naporafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05907304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907304.